CD19 CAR mRNA (Cap1, m1Ψ)

CD19 CAR mRNA encodes a chimeric antigen receptor targeting B cells. Features Cap1, m1Ψ modification, and 100A tail for transient, non-integrating CAR expression. Ideal for generating CAR immune cells for B-cell malignancy research.

价格	￥1500
产品编号	RP-A00079-0.2
规格	0.2 mg 大单询价
数量

产品属性质控参数应用指导图例

Description

The CD19 CAR mRNA encodes a chimeric antigen receptor (CAR) that specifically recognizes the CD19 antigen on B cells. This mRNA enables transient CAR expression in immune effector cells, such as T cells or NK cells, allowing them to target and eliminate CD19+ cells. The CAR typically includes an extracellular scFv specific to CD19, a hinge and transmembrane domain, and intracellular signaling domains (e.g., CD28 or 4-1BB and CD3ζ) for activation and persistence.

This mRNA features:
- A Cap1 structure with high capping efficiency for enhanced translation
- 100% substitution with N1-methyl-pseudouridine (m1Ψ) to improve protein expression and reduce innate immune activation
- A 100A poly(A) tail to mimic mature mRNA

This CD19 CAR mRNA is ideal for generating CAR-expressing immune cells for research and preclinical studies targeting B-cell malignancies such as acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma.

产品属性

Form	Liquid
Concentration	1mg/mL
Full mRNA length	1789 nt
Full mRNA Molecular Weight	578298 Da
Storage buffer	1mM Sodium citrate, pH 6.5
Storage condition	Store at -20°C for short term (<3 months), store at -80°C for long term.

质控参数

Appearance	Clear and free of foreign particles
RNA Length	Expected size band detected
RNA Content	Target ± 5%
Integrity	≥ 75%
OD260/OD280	1.70 ~ 2.30
Capping Efficiency	≥ 90%
Endotoxin	< 10 EU/mg
pH	Target ± 0.5

应用指导

NFAT Activation Assay (Luciferase) – CD19 CAR mRNA:
Jurkat cells were transfected with CD19 CAR mRNA and subsequently co-incubated with NLAM cells expressing the CD19 antigen to assess CAR-mediated signaling. Activation of the CAR triggered the NFAT signaling pathway, leading to luciferase expression under NFAT-responsive promoter control. The resulting luminescence intensity served as a quantitative measure of NFAT activation — where higher luminescence indicates stronger CAR activation and higher binding affinity between the CD19 CAR and its antigen. This assay provides a functional readout of CAR engagement and signaling potency.

图例

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.